Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

Teva Pharmaceuticals is being fined $503 million (€463 million) by the European Commission for delaying competition posed by ...

Operator Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited earnings conference call. My name is Alex, ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday ...

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) will be announcing its earnings results before the market opens ...

The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly ...

Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns ...

Prasad covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Elanco Animal Health, and Jazz Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst ...

Teva Pharmaceutical (TEVA) stock gains in premarket after the company posted better than expected Q3 2024 financials and ...

In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...

On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its ...